Suzetrigine (VX-548) is a non-opioid, small-moleculeanalgesic that works as a selective inhibitor of Nav1.8-dependant pain signaling pathways in the peripheral nervous system.[1] It is being developed by Vertex Pharmaceuticals and has completed two Phase III trials.[2]
Vertex announced in January 2024 that VX-548 successfully met several endpoints in its Phase III trials. The drug relieved moderate to severe post-surgical pain. Vertex hopes the drug, which operates on peripheral nerves, will avoid the addictive potential of opioids.[2][3]
Vertex also plans to seek a broad label for peripheral neuropathic pain, citing positive Phase 2 results in painful diabetic peripheral neuropathy (DPN).[2]